None
Undercover FBI agents were not present during the 2021 attack on the US Capitol by Donald Trump supporters, a Justice Department watchdog said Thursday in a report debunking a popular right-wing conspiracy theory. "We found no evidence in the materials we reviewed or the testimony we received showing or suggesting that the FBI had undercover employees in the various protest crowds, or at the Capitol, on January 6," Justice Department inspector general Michael Horowitz said in an 88-page report. Thousands of Trump supporters stormed the US Capitol on January 6 in a bid to prevent congressional certification of Democrat Joe Biden's election victory. Right-wing media and even some Republican lawmakers have spuriously claimed that undercover FBI agents provoked the attack on Congress, which followed a fiery speech by Trump in which he falsely claimed the election had been stolen. The inspector general said that while no undercover FBI agents were present at the Trump rally or the Capitol, 26 FBI informants known as confidential human sources (CHS) were in Washington at the time. Three of the informants had been tasked with reporting on domestic terrorist suspects while the others were there on their own. "None of these FBI CHSs were authorized to enter the Capitol or a restricted area, or to otherwise break the law on January 6, nor was any CHS directed by the FBI to encourage others to commit illegal acts on January 6," the report said. The inspector general also said there had been an intelligence-gathering failure by the FBI ahead of the January 6 attack. "While the FBI undertook significant efforts to identify domestic terrorism subjects who planned to travel to the Capital region on January 6," the report said, "the FBI did not take a step that could have helped the FBI and its law enforcement partners with their preparations. "Specifically, the FBI did not canvass its field offices in advance of January 6, 2021, to identify any intelligence, including CHS reporting, about potential threats to the January 6 Electoral Certification," it said. FBI deputy director Paul Abbate was quoted as saying this was a "basic step that was missed" in "understanding the threat picture prior to January 6." Trump was impeached by the Democratic-majority House of Representatives following the attack on the Capitol, but acquitted by the Senate. He is to return to the White House on January 20 after defeating Vice President Kamala Harris in the November presidential election. More than 1,500 people have been charged in connection with the assault on Congress. Trump has lauded them as "patriots" and "political prisoners" and pledged to pardon many of them when he returns to the White House. cl/st
Discover the VP (Vortex Protocol) Listing on XTMerrimack holds Fordham to 31 yards offense in 19-3 win
WASHINGTON (AP) — President-elect Donald Trump’s allies on Capitol Hill rallied around Pete Hegseth , Trump’s Pentagon pick, on Thursday even as new details surfaced about allegations that he had sexually assaulted a woman in 2017. The GOP embrace of Hegseth came as another controversial Trump nominee, Matt Gaetz, withdrew from consideration for attorney general. Gaetz said it was clear he had become a “distraction" amid pressure on the House to release an ethics report about allegations of his own sexual misconduct. An attorney for two women has said that his clients told House Ethics Committee investigators that Gaetz paid them for sex on multiple occasions beginning in 2017, when Gaetz was a Florida congressman. Fresh questions over the two nominees' pasts, and their treatment of women, arose with Republicans under pressure from Trump and his allies to quickly confirm his Cabinet. At the same time, his transition has so far balked at the vetting and background checks that have traditionally been required. While few Republican senators have publicly criticized any of Trump's nominees, it became clear after Gaetz's withdrawal that many had been harboring private concerns about him. Oklahoma Sen. Markwayne Mullin, who served with Gaetz in the House, said it was a “positive move.” Mississippi Sen. Roger Wicker said it was a “positive development.” Maine Sen. Susan Collins said Gaetz “put country first and I am pleased with his decision.” After meeting with Hegseth, though, Republicans rallied around him. “I think he’s going to be in pretty good shape,” said Wicker, who is expected to chair the Senate Armed Services Committee in the next Congress. Republican senators' careful words, and their early reluctance to publicly question Trump's picks, illustrated not only their fear of retribution from the incoming president but also some of their hopes that the confirmation process can proceed normally, with proper vetting and background checks that could potentially disqualify problematic nominees earlier. Gaetz withdrew after meeting with senators on Wednesday. Sen. Thom Tillis said Gaetz was “in a pressure cooker” when he decided to withdraw, but suggested that it would have little bearing on Trump’s other nominees. “Transactions — one at a time,” he said. As the Hegseth nomination proceeds, Republicans also appear to be betting that they won't face much backlash for publicly setting aside the allegations of sexual misconduct — especially after Trump won election after being found liable for sexual abuse last year. Hegseth held a round of private meetings alongside incoming Vice President JD Vance on Thursday in an attempt to shore up support and told reporters afterward: “The matter was fully investigated and I was completely cleared, and that’s where I’m gonna leave it.” A 22-page police report report made public late Wednesday offered the first detailed account of the allegations against him. A woman told police that she was sexually assaulted in 2017 by Hegseth after he took her phone, blocked the door to a California hotel room and refused to let her leave. The report cited police interviews with the alleged victim, a nurse who treated her, a hotel staffer, another woman at the event and Hegseth. Hegseth’s lawyer, Timothy Palatore, said the incident was “fully investigated and police found the allegations to be false.” Hegseth paid the woman in 2023 as part of a confidential settlement to head off the threat of what he described as a baseless lawsuit, Palatore has said. Wicker played down the allegations against Hegseth, a former Fox News host, saying that “since no charges were brought from the authorities, we only have press reports.” Sen. Bill Hagerty, R-Tenn., said after his meeting with Hegseth that he "shared with him the fact that I was saddened by the attacks that are coming his way.” Hagerty dismissed the allegations as “a he-said, she-said thing” and called it a “shame” that they were being raised at all. The senator said attention should instead be focused on the Defense Department that Hegseth would head. It's one of the most complex parts of the federal government with more than 3 million employees, including military service members and civilians. Sexual assault has been a persistent problem in the military, though Pentagon officials have been cautiously optimistic they are seeing a decline in reported sexual assaults among active-duty service members and the military academies. Wyoming Sen. John Barrasso, who will be the No. 2 Republican in the Senate next year, said after his meeting with Hegseth that the nominee is a strong candidate who “pledged that the Pentagon will focus on strength and hard power – not the current administration’s woke political agenda.” Senate Republicans are under pressure to hold hearings once they take office in January and confirm nominees as soon as Trump is inaugurated, despite questions about whether Trump’s choices will be properly screened or if some, like Hegseth, have enough experience for the job. Senate Armed Services Chairman Jack Reed, who will be the top Democrat on the panel next year, said the reports on Hegseth “emphasized the need for a thorough investigation by the FBI on the background of all the nominees.” It takes a simple majority to approve Cabinet nominations, meaning that if Democrats all opposed a nominee, four Republican senators would also have to defect for any Trump choice to be defeated. Trump has made clear he’s willing to put maximum pressure on Senate Republicans to give him the nominees he wants – even suggesting at one point that they allow him to just appoint his nominees with no Senate votes. But senators insist, for now, that they are not giving up their constitutional power to have a say. “The president has the right to make the nominations that he sees fit, but the Senate also has a responsibility for advice and consent,” said Republican Sen. Mike Rounds of South Dakota. In the case of Gaetz, he said, “I think there was advice offered rather than consent.”
GREEN BAY, Wis. (AP) — Green Bay Packers wide receiver Romeo Doubs left his team’s game against the San Francisco 49ers on Sunday because of a concussion. Doubs’ injury came on a third-quarter play in the end zone that resulted in a pass interference penalty against San Francisco’s Renardo Green. Doubs stayed down briefly after the play, then got up slowly before heading to the sideline. He went into the injury tent before walking to the locker room. The Packers then announced Doubs was out for the rest of the game because of a concussion. He had three catches for 54 yards before leaving. San Francisco defensive tackle Jordan Elliott left in the first half of the game to get evaluated for a concussion and was ruled out at halftime. AP NFL: https://apnews.com/hub/NFLAll Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinical and translational data from the Company’s FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, CA. The first three study patients, each of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. There were no dose-limiting toxicities (DLTs), no events of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. FT819 is the Company’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking. “We continue to be very pleased with early clinical observations of fludarabine-free conditioning and FT819 off-the-shelf, CAR T-cell therapy in patients with moderate-to-severe SLE. The remarkable experience of the first patient treated in April is ongoing, as the patient remains on-study in drug-free clinical remission. In addition, the initial clinical and translational data from the two additional patients treated at the first dose level continue to support the potential for disease transformation,” said Bob Valamehr, President of Research and Development of Fate Therapeutics. “We are now initiating dose expansion at this first dose level to accelerate development, and are also escalating dose based on the favorable safety profile observed. In addition, I am pleased to announce that the first patient has now been treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy. We believe our therapeutic approach is highly-differentiated and has the potential to transform disease outcomes without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy, and extended hospitalization.” FT819 Phase 1 Autoimmunity Study The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe SLE is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819 (NCT06308978). The first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360 million cells. In all three patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. All three patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD. Based on these clinical observations, the Company is initiating dose expansion in up to 10 patients at this first dose level, and is also escalating dose to 720 million cells. The Company’s FT819 Phase 1 Autoimmunity study also includes a second treatment arm to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The first patient has now been treated in this second arm, which is being conducted in parallel with the study’s conditioning arm. FT819 Patient 1 Case Study The first patient treated in the Phase 1 Autoimmunity study presented with active LN and severe disease, which was marked by renal BILAG A (British Isles Lupus Assessment Group) disease activity score based on biopsy, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) score of 20, FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) score of 33 (range 0-52, where a score of 52 indicates no fatigue) and PGA (Physician Global Assessment) score of 2.5 (where a score of 3 indicates most severe activity). Following administration of fludarabine-free conditioning and treatment with a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events (AEs) after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment, and B-cell recovery by Month 3 was predominantly comprised of naïve, non-class switched B cells with near-complete elimination of switched memory B cells and deep depletion of plasmablasts, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at Month 3. The patient achieved DORIS (definition of remission in SLE) clinical remission, including with resolution of arthritis and active urinary sediment and with a substantial reduction in proteinuria, as of Month 6 follow-up. The patient continues on-study, in DORIS clinical remission, and remains free of all immunosuppressive therapy. iPSC-derived CAR T-cell Product Platform The Company also highlighted the scientific progress of its proprietary iPSC-derived CAR T-cell product platform at the ASH Annual Meeting. In an oral presentation entitled “ Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy ”, the Company compared its novel Sword & Shield technology, which utilizes a 4-1BB-targeted CAR (ADR) alongside the complete knock-out of CD58 (CD58KO) to both target and evade host alloreactive immune cells, to other host immune evasion strategies. In preclinical studies of allogeneic models, the Company showed that its Sword and Shield Technology specifically engaged with alloreactive T cells and supported functional persistence while avoiding the killing of general host T cells and activated anti-tumor T cells. This unique observation was not seen with other approaches that are either too broad and undesirably eliminate most of the host immune system or have limited coverage and cannot adequately protect the allogeneic cell product. In a second presentation entitled “ Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells ”, the Company conducted a series of high-resolution analyses to show stimulated iPSC-derived T cells elicit primary T-cell like activation, proliferation, transcriptional and functional program engagement, and iPSC-derived CAR T cells uniquely emulate antigen-mediated response similar to primary-derived autologous CAR T cells. About Fate Therapeutics’ iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com . Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company’s iPSC-derived CAR T-cell product candidates, including FT819, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the expected clinical development plans for FT819, the initiation and continuation of enrollment in the Company’s clinical trials, the initiation of additional clinical trials and additional dose cohorts in ongoing clinical trials of the Company’s product candidates, the timing and availability of data from the Company’s clinical trials, the therapeutic and market potential of the Company’s research and development programs and product candidates, the Company’s clinical and product development strategy, and the Company’s expectations regarding progress, plans, and timelines. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties or delays in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact: Christina Tartaglia Precision AQ 212.362.1200 christina.tartaglia@precisionaq.comMutual of America Capital Management LLC Increases Holdings in Tenable Holdings, Inc. (NASDAQ:TENB)
BEREA, Ohio (AP) — The Cleveland Browns have again restructured quarterback Deshaun Watson's massive contract to create salary-cap space and give them future flexibility, a person familiar with the move told The Associated Press on Friday. Watson has been limited to just 19 games in three seasons because of an NFL suspension and injuries with the Browns, who signed him to a five-year, $230 million fully guaranteed contract in 2022. The restructuring allows the team to spread out the salary-cap hit after the 2026 season, said the person, who spoke on condition of anonymity because the team does not disclose contract specifics. The 29-year-old Watson has two years remaining on his contract with an average of $46 million a year, and with a salary-cap hit of $72.9 million in those seasons. The agreement to restructure his deal will not preclude the Browns from adding talent at the quarterback position in 2025, the person said. Watson played in only seven games this season before suffering a ruptured Achilles tendon. He's 9-10 as a starter with Cleveland. The Browns (3-12) have been a major disappointment after making it to the playoffs a year ago behind Joe Flacco, who was signed as a free agent after Watson suffered a season-ending shoulder injury. Watson had surgery in October and is expected to make a full recovery. While the team hasn't disclosed its plans at quarterback, it's assumed Watson will be in the mix to be the starter next season. It's also possible the Browns will draft a quarterback in the first round. The team hasn't had a first-round pick the past three years after trading three to the Houston Texans to acquire Watson, who was once considered one of the league's elite QBs. Watson's disappointing tenure has been a sore spot with Cleveland fans, who had hoped the team had finally resolved its interminable QB issues when they signed the three-time Pro Bowler three years ago. But it hasn't worked out, and the major investment in Watson and the salary-cap ramifications of his contract — the largest fully guaranteed deal in league history — have made it difficult for the Browns to upgrade their roster. Watson has shown flashes of being a competent starting quarterback, but there have been just as many moments in which he's looked hesitant in the pocket or unable to connect with receivers down field. Watson was suspended for the first 11 games of his first season in Cleveland after an independent arbiter ruled he violated the conduct policy after he was accused by more than two dozen women of sexual misconduct during massage therapy sessions. Since having surgery, Watson has been rehabbing his Achilles injury. He has not spoken to reporters for months. On Thursday, he posted a photo of himself on Instagram standing without wearing a walking boot. The caption read: “Back on My Feet! MOREGLORY!” Last week, Browns defensive star Myles Garrett caused a stir by saying he did not want to be part of a rebuild in Cleveland. Garrett also made it clear he wanted to know the team's offseason plans, including what the Browns intended to do at quarterback. On Friday, Garrett said he had “a few” discussions this week with the team's front office following his comments. The reigning Defensive Player of the Year didn't reveal any specifics of the talks. “They just wanted to see where my head was at and what I was thinking and just trying to keep things in house, in house,” he said. Garrett was asked if he got a favorable reaction from teammates. “They want to know what’s coming next as well,” he said. “So I haven’t really heard too many people speak up on whether they liked my comments or not. Everyone’s kind of feeling the same way. But I’m not going to assume and I’ll have my answer at the end of the year.” AP NFL: https://apnews.com/hub/NFLThe secret to making successful financial New Year’s resolutionsPublished 21:01 IST, November 23rd 2024 The counting of votes in the Jarmundi assembly concluded on Saturday, November 23. BJP's Devendra Kunwar won Jarmundi with 94892 votes. Jarmundi Election Results 2024: The counting of votes in the Jarmundi assembly concluded on Saturday, November 23. The Bharatiya Janata Party (BJP) leader Devendra Kunwar won Jarmundi assembly with a margin of 94892 votes. INC had won from the Jarmundi seat during the last Jharkhand Assembly election. Stay with us, as we bring you the latest updates on Jarmundi assembly election results. Jarmundi has been an important seat, and all eyes are on the results this year. Jharkhand Assembly Election Result 2024 To find out which candidate is leading and who is trailing in all 81 assembly seats of Jharkhand, visit republicworld.com . BJP's Devendra Kunwar won Jarmundi with 94892 votes. The counting of votes in Jarmundi has come to an end. Devendra Kunwar of BJP has won the Jarmundi seat, having polled 94892 votes. Voting Held on November 20 The Jarmundi constituency went to polls on November 20 during the second phase of the Jharkhand Assembly elections. The voting process saw active participation from voters, reflecting the importance of this seat in the state’s political landscape. Jharkhand’s elections were held in two phases, with the first phase conducted on November 13. Key Candidates in Jarmundi This election saw a tough contest between major political parties and independent candidates. The Bharatiya Janata Party (BJP) fielded Devendra Kunwar, while the Congress -Jharkhand Mukti Morcha (JMM) alliance brought back its sitting MLA, Badal, to defend the seat. Other prominent candidates included Lalmohan Ray from BSP, Amrendra Kumar from SP, Kedar Das from BMP, and many independent candidates like Juli Yadav, Devendra Mandal, and Dhiraj Kumar. Results Expected Today The counting process is expected to finish by the evening, and the results will be announced today. Voters and political analysts are eagerly waiting to see if Congress can retain the seat or if BJP or another candidate will emerge victorious. The results for all 81 assembly constituencies in Jharkhand will also be declared today. What Happened in 2019? In the 2019 Jharkhand Assembly elections, Badal from the Indian National Congress (INC) won the Jarmundi seat. He defeated BJP’s Devendra Kunwar by a margin of over 3,000 votes. Badal received 52,507 votes, while Kunwar got 49,408 votes. Congress secured 32.2% of the total votes, making it a significant win for the party in this region. This year, the contest in Jarmundi is being closely watched as political parties compete to secure a stronghold in the state. Stay updated with results to see which candidate claims victory in Jarmundi. Get Current Updates on India News , Entertainment News along with Latest News and Top Headlines from India and around the world. 04:27 IST, November 23rd 2024
Friendly reminder |
The authenticity of this information has not been verified by this website and is for your reference only. Please do not reprint without permission. If authorized by this website, it should be used within the scope of authorization and marked with "Source: this website". |
Special attention |
Some articles on this website are reprinted from other media. The purpose of reprinting is to convey more industry information, which does not mean that this website agrees with their views and is responsible for their authenticity. Those who make comments on this website forum are responsible for their own content. This website has the right to reprint or quote on the website. The comments on the forum do not represent the views of this website. If you need to use the information provided by this website, please contact the original author. The copyright belongs to the original author. If you need to contact this website regarding copyright, please do so within 15 days. |